{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T10:16:43Z","timestamp":1783160203693,"version":"3.54.6"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"10","funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"ISCIII","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002924","name":"FEDER","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,10,1]]},"DOI":"10.1093\/jac\/dkx223","type":"journal-article","created":{"date-parts":[[2017,6,13]],"date-time":"2017-06-13T07:08:10Z","timestamp":1497337690000},"page":"2850-2856","source":"Crossref","is-referenced-by-count":15,"title":["Efficacy and safety of direct antiviral agents in a cohort of cirrhotic HCV\/HIV-coinfected patients"],"prefix":"10.1093","volume":"72","author":[{"given":"Jordi","family":"Navarro","sequence":"first","affiliation":[{"name":"Hospital Universitari de la Vall d\u2019Hebron, Universitat Aut\u00f2noma de Barcelona, Barcelona, Espa\u00f1a"},{"name":"Institut de Recerca Hospital Vall d\u2019Hebron, Barcelona, Espa\u00f1a"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Laguno","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednic de Barcelona, Barcelona, Espa\u00f1a"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helem Haydee","family":"Vilchez","sequence":"additional","affiliation":[{"name":"Hospital Universitari de Son Espases, Palma de Mallorca, Espa\u00f1a"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose M","family":"Guardiola","sequence":"additional","affiliation":[{"name":"Hospital de la Santa Creu i Sant Pau, Barcelona, Espa\u00f1a"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose A","family":"Carrion","sequence":"additional","affiliation":[{"name":"Hospital del Mar, Institut Hospital del Mar d\u2019Investigacions M\u00e8diques (IMIM), Universitat Aut\u00f2noma de Barcelona (UAB), Barcelona, Espa\u00f1a"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Force","sequence":"additional","affiliation":[{"name":"Hospital de Matar\u00f3, Matar\u00f3, Espa\u00f1a"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireia","family":"Cair\u00f3","sequence":"additional","affiliation":[{"name":"Hospital Universitari M\u00fatua de Terrassa, Terrassa, Espa\u00f1a"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Cifuentes","sequence":"additional","affiliation":[{"name":"Hospital de Son Ll\u00e0tzer, Palma de Mallorca, Espa\u00f1a"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Vilar\u00f3","sequence":"additional","affiliation":[{"name":"Hospital Universitari de Vic, Vic, Espa\u00f1a"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Cucurull","sequence":"additional","affiliation":[{"name":"Hospital de Figueres, Figueres, Espa\u00f1a"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Marco","sequence":"additional","affiliation":[{"name":"Programa Penitenciari, Institut Catal\u00e0 de la Salut, Barcelona, Espa\u00f1a"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merc\u00e8","family":"Roget","sequence":"additional","affiliation":[{"name":"Consorci Sanitari de Terrassa, Terrassa, Espa\u00f1a"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Erice","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3 privada Hospital de Mollet, Mollet del Vall\u00e8s, Espa\u00f1a"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Crespo","sequence":"additional","affiliation":[{"name":"Complexo Hospitalario Universitario de Vigo, IIS Galicia Sur, Espa\u00f1a"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Catalano-Balear Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Members of the Catalano-Balear Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Crespo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merc\u00e8","family":"Roget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Aparicio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Laguno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Mallolas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Mart\u00ednez","family":"Rebollar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Cucurull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Antonio","family":"Carri\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Puigveh\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Force","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Barrufet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Sempere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Erice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep M","family":"Guardiola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireia","family":"Cair\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helem Haydee","family":"Vilchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Cifuentes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merc\u00e8","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Vilar\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Marco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Sarriera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imma","family":"Valls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,7,13]]},"reference":[{"key":"key\n\t\t\t\t20180328141326_dkx223-B1","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0140-6736(14)60494-3","article-title":"Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"384","author":"Jacobson","year":"2014","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328141326_dkx223-B2","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328141326_dkx223-B3","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa1501315","article-title":"Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1","volume":"373","author":"Naggie","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328141326_dkx223-B4","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1001\/jama.2015.1328","article-title":"Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial","volume":"313","author":"Sulkowski","year":"2015","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180328141326_dkx223-B5","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1056\/NEJMoa1503153","article-title":"Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1","volume":"373","author":"Wyles","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328141326_dkx223-B6","doi-asserted-by":"crossref","first-page":"e319","DOI":"10.1016\/S2352-3018(15)00114-9","article-title":"Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial","volume":"2","author":"Rockstroh","year":"2015","journal-title":"Lancet HIV"},{"key":"key\n\t\t\t\t20180328141326_dkx223-B7","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jhep.2016.09.001","article-title":"EASL recommendations on treatment of hepatitis C 2016","volume":"66","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J Hepatol"},{"key":"key\n\t\t\t\t20180328141326_dkx223-B8","author":"AASLD"},{"key":"key\n\t\t\t\t20180328141326_dkx223-B9","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","article-title":"Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study","volume":"384","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328141326_dkx223-B10","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328141326_dkx223-B11","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/hep.27726","article-title":"All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study","volume":"61","author":"Nelson","year":"2015","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20180328141326_dkx223-B12","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa1402869","article-title":"ABT-450\/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis","volume":"370","author":"Poordad","year":"2014","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328141326_dkx223-B13","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hep.20506","article-title":"Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C","volume":"41","author":"Ziol","year":"2005","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20180328141326_dkx223-B14","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.ultrasmedbio.2003.07.001","article-title":"Transient elastography: a new noninvasive method for assessment of hepatic fibrosis","volume":"29","author":"Sandrin","year":"2003","journal-title":"Ultrasound Med Biol"},{"key":"key\n\t\t\t\t20180328141326_dkx223-B15","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/hep.28422","article-title":"Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: a phase 3 study (OPTIMIST-2)","volume":"64","author":"Lawitz","year":"2016","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20180328141326_dkx223-B16","year":"2016"},{"key":"key\n\t\t\t\t20180328141326_dkx223-B17","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/apt.13883","article-title":"Simeprevir in combination with sofosbuvir in treatment-na\u00efve and -experienced patients with hepatitis C virus genotype 4 infection: a Phase III, open-label, single-arm study (PLUTO)","volume":"45","author":"Buti","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20180328141326_dkx223-B18","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1214854","article-title":"Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options","volume":"368","author":"Jacobson","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328141326_dkx223-B19","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection","volume":"373","author":"Foster","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328141326_dkx223-B20","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1002\/hep.28473","article-title":"Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY-3+)","volume":"63","author":"Leroy","year":"2016","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20180328141326_dkx223-B21","doi-asserted-by":"crossref","first-page":"S265","DOI":"10.1016\/S0168-8278(15)30159-8","article-title":"LP05: Daclatasvir plus sofosbuvir with or without ribavirin in patients with HCV genotype 3 infection: interim analysis of a French multicenter compassionate use program","volume":"62","author":"Hezode","year":"2015","journal-title":"J Hepatol"},{"key":"key\n\t\t\t\t20180328141326_dkx223-B22","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1136\/gutjnl-2016-312444","article-title":"Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort","volume":"65","author":"Welzel","year":"2016","journal-title":"Gut"},{"key":"key\n\t\t\t\t20180328141326_dkx223-B23"},{"key":"key\n\t\t\t\t20180328141326_dkx223-B24","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jhep.2015.03.025","article-title":"EASL recommendations on treatment of hepatitis C 2015","volume":"63","author":"European Association for Study of Liver","year":"2015","journal-title":"J Hepatol"},{"key":"key\n\t\t\t\t20180328141326_dkx223-B25","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.27950","article-title":"Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus","volume":"62","year":"2015","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20180328141326_dkx223-B26","first-page":"1270A","article-title":"Ledipasvir\/sofosbuvir fixed dose combination is safe and efficacious in cirrhotic patients who have previously failed protease-inhibitor based triple therapy","volume":"60","author":"Bourli\u00e8re","year":"2014","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20180328141326_dkx223-B27","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/hep.28446","article-title":"Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence","volume":"63","author":"Poordad","year":"2016","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20180328141326_dkx223-B28","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s10620-014-3422-x","article-title":"Hepatic decompensation likely attributable to simeprevir in patients with advanced cirrhosis","volume":"60","author":"Stine","year":"2015","journal-title":"Dig Dis Sci"},{"key":"key\n\t\t\t\t20180328141326_dkx223-B29","doi-asserted-by":"crossref","first-page":"S137.","DOI":"10.1016\/S0168-8278(16)01641-X","article-title":"The real-world Israeli experience of treating chronic hepatitis C, genotype 1 patients with advanced fibrosis with paritaprevir\/ritonavir\/ombitasvir, dasabuvir with or without ribavirin: a large multi-center cohort","volume":"64","author":"Zuckerman","year":"2016","journal-title":"J Hepatol"},{"key":"key\n\t\t\t\t20180328141326_dkx223-B30","author":"Olysio Prescribing Information"},{"key":"key\n\t\t\t\t20180328141326_dkx223-B31","author":"Viekirax Prescribing Information"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/72\/10\/2850\/21587564\/dkx223.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,3,28]],"date-time":"2018-03-28T15:56:50Z","timestamp":1522252610000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/72\/10\/2850\/3959885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,13]]},"references-count":31,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2017,7,13]]},"published-print":{"date-parts":[[2017,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkx223","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,10]]},"published":{"date-parts":[[2017,7,13]]}}}